Lost in the debate over how Medicare will negotiate drug prices, there's a concern by federal agencies about a metric used in determining a drug’s value. It's known as the Quality-Adjusted Life Year. There's bipartisan agreement in not using the term QALY, and “not even Medicare officials have signaled they want to use that approach.” What exactly are they talking about?
ICER
Remdesivir appears to be our first promising treatment for COVID-19. It is certainly neither a cure nor a preventative. But it seems to reduce the length of hospital stays, and thus, increases the health systems’ capacity by about a third. So if you were in charge of selling this drug, what price would you set?